ArticleCancer management and research2026
Evaluation of DNA Methylation in TAC1, SOX17, and RASSF1A for the Early Diagnosis of Lung Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-Dose Computed Tomography (LDCT) is commonly used to detect pulmonary nodules; however, it may also contribute to overdiagnosis. DNA methylation shows promise as an approach to discriminate early-stage lung cancer (LC) patients from individuals with benign nodules (hereafter referred to as benign pulmonary nodule group) and healthy individuals. Methods: This study investigated the performance of DNA methylation in three genes ( Results: Methylation-positive rates for all three genes were significantly higher in LC patients compared to benign/healthy individuals. A combined three-gene model based on the ΔCt values of the three genes demonstrated robust diagnostic performance, achieving a sensitivity of 97.7%, specificity of 96.6%, and an area under the curve (AUC) of 0.99 for discriminating LC patients from benign/healthy individuals. Furthermore, another combined three-gene model based on the ΔCt values of the same genes showed high diagnostic performance for discriminating IA-stage LC patients from benign/healthy individuals, with a sensitivity of 96.9%, specificity of 88.54%, and AUC of 0.95. Conclusion: This study highlights the robust diagnostic value of a combined three-gene (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.